Real-world outcomes of the efficacy and safety of polatuzumab vedotin combination regimen in patients with relapsed/refractory diffuse large B cell lymphoma
Yuanfei Shi,
Yi Xu,
Jinghan Wan
et al.
Abstract:Objective Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL), with approximately 60% of patients being successfully treated with R-CHOP therapy. However, a significant proportion, around 40%-45%, do not respond to initial treatment or experience relapse, leading to a poor prognosis for this patient group. Therefore, the exploration of targeted drugs and combination therapies is crucial. Among these options, polatuzumab vedotin (Pola), an anti-CD79B antibody-drug conj… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.